(Q27851583)

English

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer (English)

1 reference

13 November 2016

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

I J Dahabreh

1

0 references

H Linardou

2

0 references

P Kosmidis

3

0 references

D Bafaloukos

4

0 references

S Murray

5

0 references

publication date

March 2011

0 references

Annals of Oncology

0 references

22

0 references

545-52

0 references

3

0 references

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Why the epidermal growth factor receptor? The rationale for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Interaction revisited: the difference between two estimates

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

EGFR FISH versus mutation: different tests, different end-points.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Issues in using progression-free survival when evaluating oncology products

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Controlling the risk of spurious findings from meta-regression.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Lung cancer in never smokers: a review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Molecular genetics of lung cancer in people who have never smoked

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Population-based differences in treatment outcome following anticancer drug therapies.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Ecological bias, confounding, and effect modification

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ432

21 January 2018

Identifiers

10.1093/ANNONC/MDQ432

0 references

1 reference

13 November 2016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851583&oldid=1989513535"